LT2890680T - N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius - Google Patents

N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius

Info

Publication number
LT2890680T
LT2890680T LTEP13760222.3T LT13760222T LT2890680T LT 2890680 T LT2890680 T LT 2890680T LT 13760222 T LT13760222 T LT 13760222T LT 2890680 T LT2890680 T LT 2890680T
Authority
LT
Lithuania
Prior art keywords
morpholinophenyl
fluorobenzyl
pyridin
acetamide
tyrosine kinase
Prior art date
Application number
LTEP13760222.3T
Other languages
English (en)
Inventor
David Hangauer
Original Assignee
Athenex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex, Inc. filed Critical Athenex, Inc.
Publication of LT2890680T publication Critical patent/LT2890680T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEP13760222.3T 2012-08-30 2013-08-30 N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius LT2890680T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695100P 2012-08-30 2012-08-30
US201361779868P 2013-03-13 2013-03-13
PCT/US2013/057565 WO2014036426A1 (en) 2012-08-30 2013-08-30 N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) acetamide as protein|tyrosine kinase modulators

Publications (1)

Publication Number Publication Date
LT2890680T true LT2890680T (lt) 2018-05-10

Family

ID=49162280

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13760222.3T LT2890680T (lt) 2012-08-30 2013-08-30 N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius

Country Status (12)

Country Link
US (5) US9926273B2 (lt)
EP (1) EP2890680B1 (lt)
JP (3) JP6499076B2 (lt)
KR (1) KR102346033B1 (lt)
CN (2) CN105263907B (lt)
CA (1) CA2883144C (lt)
ES (1) ES2664332T3 (lt)
HU (1) HUE037637T2 (lt)
LT (1) LT2890680T (lt)
SI (1) SI2890680T1 (lt)
TW (1) TWI664167B (lt)
WO (1) WO2014036426A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
LT2890680T (lt) 2012-08-30 2018-05-10 Athenex, Inc. N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius
CN106902358B (zh) * 2015-12-21 2020-07-10 广州市香雪制药股份有限公司 口服制剂及其制备方法
CN106902357B (zh) * 2015-12-21 2021-08-03 广州市香雪制药股份有限公司 药物组合物及其应用、药物包合物、静脉制剂及制备方法
CN114516832B (zh) * 2020-11-20 2023-11-28 成都贝诺科成生物科技有限公司 一种微管蛋白抑制剂及其制备方法与应用
CN113354575B (zh) * 2021-06-07 2022-09-27 河南应用技术职业学院 一种特班布林的合成方法
CN115477608B (zh) * 2021-06-16 2023-12-12 成都贝诺科成生物科技有限公司 一种微管蛋白抑制剂及其制备方法与应用
WO2023134753A1 (zh) * 2022-01-14 2023-07-20 武汉人福创新药物研发中心有限公司 微管蛋白-src双靶点抑制剂

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1121922A (en) 1966-06-17 1968-07-31 Ici Ltd Pyrimidine derivatives
GB1147068A (en) 1966-12-02 1969-04-02 Ici Ltd Phenyl-pyridine derivatives
US3761477A (en) 1968-11-08 1973-09-25 Mc Neil Labor Inc Pyrazineacetic acids, lower alkyl esters, amides and salts
IT1044222B (it) 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
AT341512B (de) 1975-01-09 1978-02-10 Thomae Gmbh Dr K Verfahren zur herstellung von neuen biphenylathern
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
JPS62252755A (ja) 1986-04-11 1987-11-04 Daikin Ind Ltd 新規ｎ−ベンジルベンズアミド誘導体およびこれを有効成分として含有する除草剤
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US5232948A (en) 1990-09-10 1993-08-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
CH685875A5 (fr) 1991-04-26 1995-10-31 Pierre Baudet Les N-phényl-benzamides protecteurs contre les effets nocifs de la lumière ultra-violette
WO1992020645A1 (en) 1991-05-20 1992-11-26 Tsumura & Co. Phellodendrine analogs and allergy type iv suppressor containing the same as active ingredient
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
DE4236103A1 (de) 1992-10-26 1994-04-28 Hoechst Ag Verfahren zur Kreuzkupplung von aromatischen Boronsäuren mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
FR2705671B1 (fr) 1993-05-26 1995-07-07 Inst Nat Sante Rech Med Nouveaux dérivés de l'hydroxybiphényle, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5631023A (en) 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
FR2737721B1 (fr) 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
WO1998021185A1 (en) 1996-11-08 1998-05-22 Sankyo Company, Limited Arylureas or arylmethylcarbamoyl derivatives
ATE421318T1 (de) 1997-02-20 2009-02-15 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
CA2303438A1 (en) 1997-09-09 1999-03-18 Bristol-Myers Squibb Pharma Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7070936B1 (en) 1999-01-13 2006-07-04 The Research Foundation Of State University Of New York Method for designing protein kinase inhibitors
JP2001023259A (ja) 1999-07-09 2001-01-26 Sony Corp 光磁気記録媒体およびその製造方法
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6372752B1 (en) 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
US20040039048A1 (en) 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
WO2001096307A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
JP2002020362A (ja) 2000-07-06 2002-01-23 Nippon Oruganon Kk 新規ビフェニル誘導体
ATE310719T1 (de) 2000-09-29 2005-12-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
WO2002042272A2 (en) 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
EP1373257B9 (en) 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US7547716B2 (en) 2001-06-08 2009-06-16 Institute Of Medicinal Molecular Design, Inc. Sulfonamide derivatives
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
JP2003231633A (ja) 2002-02-06 2003-08-19 Tanabe Seiyaku Co Ltd 医薬組成物
EP1472216A2 (en) 2002-02-07 2004-11-03 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
WO2004011427A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
EP1542989B1 (en) 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU2003286876A1 (en) 2002-11-01 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
ATE343583T1 (de) 2002-11-08 2006-11-15 Novo Nordisk As Halogensulfonylarylboronate
ES2571779T3 (es) 2002-12-13 2016-05-26 Ym Biosciences Australia Pty Inhibidores de cinasa a base de nicotinamida
WO2004056774A2 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PT1656370E (pt) 2003-06-03 2012-11-29 Rib X Pharmaceuticals Inc Compostos biaril-heterocíclicos e métodos de os produzir e de os utilizar
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
FR2860514A1 (fr) 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
BRPI0416283A (pt) 2003-11-05 2007-01-23 Hoffmann La Roche compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos
JP4585522B2 (ja) 2003-12-22 2010-11-24 メルク・シャープ・エンド・ドーム・コーポレイション ブラジキニン拮抗物質又は逆作用物質としてのアルファ−ヒドロキシアミド
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2005102388A1 (ja) 2004-04-26 2005-11-03 Ono Pharmaceutical Co., Ltd. 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2006071960A2 (en) 2004-12-28 2006-07-06 Kinex Pharmaceuticals, Llc Compositions and methods of treating cell proliferation disorders
WO2007026920A2 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
AU2007208239B2 (en) 2006-01-25 2013-04-18 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
WO2007095383A2 (en) 2006-02-15 2007-08-23 Myriad Genetics, Inc. Prodrugs
EP1994024A2 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
JP2009528335A (ja) * 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キナゾリン誘導体
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
AU2007265373B2 (en) 2006-06-29 2013-02-21 Atnx Spv, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008002676A2 (en) 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008005338A1 (en) 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
CN101562977A (zh) 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
AU2007336781C1 (en) 2006-12-21 2014-10-09 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US20100256147A1 (en) 2007-04-13 2010-10-07 Hangauer Jr David G Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders
AU2008254500B2 (en) * 2007-05-17 2014-01-23 Atnx Spv, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2558085B1 (en) * 2010-04-16 2017-08-30 Athenex, Inc. Compositions and methods for the prevention and treatment of cancer
LT2890680T (lt) 2012-08-30 2018-05-10 Athenex, Inc. N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius

Also Published As

Publication number Publication date
JP2021006580A (ja) 2021-01-21
JP6499076B2 (ja) 2019-04-10
TWI664167B (zh) 2019-07-01
CA2883144C (en) 2023-01-17
CN105263907B (zh) 2018-11-20
JP2019052153A (ja) 2019-04-04
ES2664332T3 (es) 2018-04-19
US20140066445A1 (en) 2014-03-06
HUE037637T2 (hu) 2018-09-28
US20230167060A1 (en) 2023-06-01
EP2890680B1 (en) 2018-02-28
WO2014036426A1 (en) 2014-03-06
US20210214305A1 (en) 2021-07-15
KR20150046329A (ko) 2015-04-29
CA2883144A1 (en) 2014-03-06
SI2890680T1 (en) 2018-08-31
US20180170875A1 (en) 2018-06-21
HK1215544A1 (zh) 2016-09-02
EP2890680A1 (en) 2015-07-08
HK1212329A1 (en) 2016-06-10
JP2015526526A (ja) 2015-09-10
US20190263755A1 (en) 2019-08-29
TW201422585A (zh) 2014-06-16
US10106505B2 (en) 2018-10-23
CN105263907A (zh) 2016-01-20
US9926273B2 (en) 2018-03-27
CN109999040A (zh) 2019-07-12
KR102346033B1 (ko) 2021-12-30

Similar Documents

Publication Publication Date Title
LT2890680T (lt) N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius
HUS2200010I1 (hu) Kondenzált heterociklusos vegyületek protein-kináz inhibitorként
HRP20190128T1 (hr) Novi spojevi kao modulatori protein kinaza
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
EP2905290A4 (en) HETERODIMER PROTEIN COMPOSITION
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
PL3409278T3 (pl) Heterocykliczne inhibitory kinazy białkowej
EP3083559A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
ZA201402549B (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
IL232333A (en) N- (pyrid-4-ram) amides and n- (pyrimidin-4-ram) amides and their pharmacological and cosmetic uses
ZA201502575B (en) Heteroaromatic compounds as pi3 kinase modulators and methods of use
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
EP2870158A4 (en) PROTEIN KINASE INHIBITORS
IL237158A0 (en) Amino quinzolines as kinase inhibitors
EP2855484A4 (en) PROTEIN KINASE INHIBITORS
EP2988749A4 (en) Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
EP2895166A4 (en) AMINOISOQUINOLINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
BR112015002078A2 (pt) inibidores antibacteriais de proteína quinase
EP3082807A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP2822687A4 (en) ANIONIC EXCHANGE HYDROPHOBIC MIXING MODE
EP3083560A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3071572A4 (en) Protein kinase inhibitors
ZA201508756B (en) N-(2-fluoro-2-phenethyl)carboxamides as nematicides and endoparasiticides
EP3074401A4 (en) Protein kinase inhibitors
EP3071573A4 (en) Protein kinase inhibitors